Form 4: Quince Therapeutics Executive Brendan Hannah Reports Stock Option Grant

Brendan Hannah, CBO, COO, and CCO of Quince Therapeutics, Inc., reports the acquisition of stock options.

Summary

• Brendan Hannah, an executive at Quince Therapeutics, filed a Form 4 with the SEC.
• The filing reports the grant of employee stock options to Hannah on January 28, 2025.
• The options allow Hannah to purchase 450,000 shares of Quince Therapeutics common stock at an exercise price of $1.60 per share.
• The options vest in equal monthly installments over four years, starting January 1, 2025, and will be fully vested by January 1, 2029.
• The options expire on January 27, 2035.
• Following the transaction, Hannah directly owns 450,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to executive compensation. It doesn't inherently convey positive or negative sentiment.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Future Outlook

This filing does not contain forward-looking statements about the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the executive to increase shareholder value.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Quince Therapeutics, Executive Compensation, QNCX, Hannah Brendan